AIML.CN AI/ML Innovations Inc. (CNQ) C$0.035 25 Mar 2026: model sees -37%

The AIML.CN stock trades at C$0.035 on 25 Mar 2026 as a thinly traded microcap in Canada’s CNQ market. Investors should note the company reports negative EPS of -0.03 and a small market cap of C$5,889,240.00. Volume today sits at 107,200 versus an average of 413,110, underscoring low liquidity. This piece examines valuation, financials, technicals and a model forecast that signals meaningful downside risk for this AI-healthcare microcap.

AIML.CN stock: current market snapshot and flow

AI/ML Innovations Inc. (AIML.CN) is priced at C$0.035 with a day range fixed at C$0.035–C$0.035. Market cap is C$5,889,240.00 and shares outstanding are 168,264,000. Average volume is 413,110, so today’s 107,200 shares represent low relative activity and a relVolume of 0.26. Limited trading depth can magnify moves and widen spreads for AIML.CN stock, which matters for entry and exit timing.

AIML.CN stock: fundamentals and valuation

AIML.CN results show EPS -0.03 and PE -1.17, reflecting persistent losses. Key ratios include Price/Sales 35.00 and Price/Book 4.58, which are high versus small peers in digital health. The balance sheet shows cash per share 0.005 and a current ratio 2.09, indicating short-term liquidity but limited cash buffers. These metrics frame AIML.CN stock as speculative with stretched valuation relative to revenue and profitability.

AIML.CN stock: technicals and trading signals

Technicals for AIML.CN stock are muted. RSI 43.36 sits below neutral, and ADX 18.65 signals no clear trend. Bollinger bands put the midpoint near C$0.04 with a lower band at C$0.03, matching the current price cluster. Volatility indicators are compressed and on low absolute values, so breakouts may be thin. Traders should expect wide bid-ask swings on higher volume days.

AIML.CN stock: sector context and competitive risks

AI/ML Innovations sits in the Healthcare sector and the Medical – Healthcare Information Services industry. The healthcare sector has underperformed YTD with -5.16% and shows negative average returns, increasing the hurdle for AI health names. AIML.CN faces competition for clinical validation, regulatory steps and customer adoption. These operational risks combine with microcap liquidity to heighten execution risk for AIML.CN stock.

AIML.CN stock: Meyka AI grade and price forecast

Meyka AI rates AIML.CN with a score out of 100: 62.09 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of C$0.020 and a yearly price of C$0.022, versus the current C$0.035, implying an estimated -37.14% downside to the one-year projection. Forecasts are model-based projections and not guarantees.

AIML.CN stock: catalysts, opportunities and key risks

Catalysts for AIML.CN stock include clinical partnerships, regulatory clearances, or product commercialization that prove the patent-pending monitoring system. Opportunities stem from demand for AI-driven digital health tools. Primary risks are low revenue per share (0.001), long days-sales-outstanding (576 days), and negative margins (net margin -39.10%). Investors should monitor news flow and filings closely; see company site and recent AI coverage for context AI/ML Innovations site and AI sector news WSJ AI coverage.

Final Thoughts

AIML.CN stock trades at C$0.035 on the CNQ market with limited liquidity and negative earnings. Our review shows stretched valuation metrics—Price/Sales 35.00, Price/Book 4.58—and operational friction such as long receivables (days sales outstanding 576). Meyka AI’s model projects C$0.022 in one year, implying roughly -37.14% from today’s price. For ranges, a conservative bear target is C$0.015 (approx -57.14%), a model-based base is C$0.022 (-37.14%), and a higher-risk upside case is C$0.060 (+71.43%) if commercialization accelerates. Meyka AI rates AIML.CN with a score out of 100: 62.09 (Grade B, HOLD). This analysis factors sector trends, financials and forecast models. Investors seeking exposure to AI in healthcare should treat AIML.CN stock as speculative, size positions small, and monitor catalysts, filings and liquidity. For live quotes and further data consult the Meyka AIML.CN page and company filings via the links above.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.